{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"145-147-229-454-954","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"145-147-229-454-954","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10791,"type":"PATENT","title":"The Hebrew University of Jerusalem - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":7593,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8259,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: \"hebrew univ* jerusalem\"; \"hebrew univ* jerus*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1457
Search Applicants and Owners separately: \"hebrew univ* jerusalem\"; \"hebrew univ* jerus*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1457
A—B designates an optional double bond,\n
R1 is (a)—R′N(R″)2 wherein R′ is C1–C5 straight or branched chain alkyl and each R″, which may be the same or different, is hydrogen or C1–C5 straight or branched chain alkyl optionally containing a terminal —OR′″ or —OC(O)R′″ moiety wherein R′″ is hydrogen or C1–C5 straight or branched chain alkyl, (b) —Q wherein Q is a heterocyclic moiety having a labile hydrogen atom so that said moiety acts as a carboxylic acid analogue, (c) —R′X wherein R′ is C1–C5 straight or branched chain alkyl and X is halogen, (d) —R′C(O)N(R″)2 wherein R′ is a direct bond or C1–C5 straight or branched chain alkyl and each R′″, which may be the same or different, is hydrogen or C1–C5 straight or branched chain alkyl optionally containing a terminal —OR′″ or —OC(O)R′″ moiety wherein R′″ is hydrogen or C1–C5 straight or branched chain alkyl, (e) —R′C(O)OR″ wherein R′ is a direct bond or C1–C5 straight or branched chain alkyl and R″ is hydrogen or C1–C5 straight or branched chain alkyl optionally containing a terminal —OR′″ or —OC(O)R′″ moiety wherein R′″ is hydrogen or C1–C5 straight or branched chain alkyl, (f) —R′ wherein R′ is C1–C5 straight or branched chain alkyl, or (g) —R′OR′″ wherein R′ is C1–C5 straight or branched chain alkyl and R′″ is hydrogen or C1–C5 alkyl;\n
G is hydrogen, halogen, or —OR2 wherein R2 is hydrogen or C1–C5 alkyl optionally containing a terminal —OR′″, —OC(O)R′″, —C(O)OR′″, or —C(O)R′″ moiety wherein R′″ is hydrogen or C1–C5 alkyl; and\n
R3 is (a) C1–C12 straight or branched chain alkyl, (b) —OR″″, in which R″″ is a straight chain or branched C2–C9 alkyl which may be substituted at the terminal carbon atom by a phenyl group, or (c) —(CH2)nOR′″ wherein n is an integer of 1 to 7 and R′″ is hydrogen or C1–C5 alkyl,\n
wherein the disease or disorder to be treated is hypertension, gastrointestinal disorders, tumors expressing CB2 receptors or autoimmune diseases and the pharmaceutical composition is administered to an individual in a therapeutically effective amount for treating the disease or disorder."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the method is for preventing, treating, or managing tumors expressing CB2 receptors."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the method is for preventing, treating, or managing hypertension."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the method is for preventing, treating, or managing autoimmune diseases."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein G is —OCH3 and R3 is 1,1-dimethyl heptyl."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein R1 is —CH2OH, G is —OCR3, and R3 is 1,1-dimethyl heptyl."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable diluent that is an aqueous cosolvent solution."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 7, wherein the diluent comprises a pharmaceutically acceptable cosolvent, a micellar or emulsion solution prepared with natural or synthetic ionic or nonionic surfactants, or a combination of such cosolvent and micellar or emulsion solutions."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein the carrier comprises a solution of ethanol, a surfactant and water or an emulsion comprising triglycerides, lecithin, glycerol, an emulsifier, an antioxidant and water."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein A—B designates a double bond, R1 is —CH2OH, G is —OCH3, and R3 is 1,1-dimethyl heptyl."],"number":11,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}